Inhibitors for in vitro and cell-based assays were obtained as follows: ponatinib (MedChemExpress (MCE), HY-12047); asciminib (MCE, HY-104010); imatinib (MCE, HY-15463); dasatinib (MCE, HY-10181); osimertinib (MCE, HY-15772); and RMC-5552 (MCE, HY-132168). DasatiLink-1 and asc-tracer were obtained from the same batches as previously described14,34. DAS-DFGO-II and DAS-CHO-II were provided by M. Soellner. Das-tracer44 was provided by Promega. Synthesis
Compounds dBET6 (HY-112588), dBRD9 (HY-117690), MLN7243 (HY-100487), MLN4924 (HY-70062), MG132 (HY-13259), bafilomycin A1 (HY-100558), and 5K Scaffold Library (HY-L902) were obtained from MedChemExpress. Plasmids The following plasmids were used in this study: Artichoke (Addgene #73320) and Cilantro (Addgene #74450) for flow-based reporter degradation assays, reporter CRISPR screens and co-immunoprecipitation; sgBFP (U6.sgRNA.SFFV.tBFP) for validation of DCAF11-knockout
